8:30 am Chair’s Opening Remarks

Clinical Case Studies & Critical Analysis of Current Data

8:40 am Vaccibody’s Clinical Study – The Importance of Different Vaccine Platforms, Neoepitope Selection & Clinical Trial design to Show Vaccine-induced Clinical Efficacy


• Exploring the contribution of TMB, heterogeneity and neoepitope quality parameters for successful outcomes

• Which patient populations could benefit from a neoantigen vaccine?

• What is the ideal combination strategy for neoantigen vaccines?

9:10 am The Impact of Stimulatory & Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical & Pre-Clinical Results


• ATLAS identifies stimulatory and inhibitory CD4+ and CD8+ T cell responses to neoantigens and common antigens

• Preclinical models show the deleterious impact of inhibitory T cell responses on anti-tumor immunity

• Be careful, common neoantigens may differ from common mutations

• The GEN-009 immunotherapy, designed with personalised ATLAS-identified stimulatory neoantigens has resulted in unprecedented breadth of immune response in the ongoing GEN-009-101 Phase 1/2a clinical trial

9:50 am Outlining the Key Considerations to Take into Account When Interacting with a Regulatory Body


• Different national agencies have different attitudes

• Make early contact with the regulator

• Regulator understands that there will be on-going validation of assays and control over processes

10:20 am Morning Refreshments & Networking


10.50 High-affinity Neoepitope-Specific T cells Accumulate in Tumours

• NeoAg-specific CD8 T cells cover broad ranges of avidities (structural and functional)

• Unlike the functional avidity, the structural avidity of neoAg-specific CD8 T cells is higher than that of TAA-specific CD8 T cells

• CD8 T cells bearing high avidity TCR better upregulate tumor-homing receptors, infiltrate tumour and control tumours

Alexandre Harari, Group leader, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne


11.20 Personalised Cancer Vaccines: Enhancing Neo-epitope Presentation

• Update on current personalized cancer vaccine clinical approach, successes and challenges

• Basic research approaches to enhance presentation of neo-epitopes via various cellular perturbations

• Show casing some high throughput targeted spectrometric tools for further characterizing epitopes for binding affinity various HLA allele and presentation

Jennie Lill, Senior Director of Proteomics & NGS, Genentech


11.50 Enriched Neoantigen Reactive TIL

• Proof of concepts in solid tumours

• MHC class I and II reactive cell product

• Polyfunctional

TJ Langer, CEO & President, Myst Therapeutics


12.20 Are Immunogenic Tumours the Best Targets of Tumour Vaccination?

• Identifying the best targets for tumour vaccination

• Tumour infiltration and PDL1expression to identify the tumours that are more sensitive to vaccines

• Assessing non immunogenic tumours

• Outlining considerations for the future of neoantigens

Kostas Kosmatopoulos, CEO, Vaxon Biotech



12:50 pm Networking Lunch

1:50 pm Exploring an Additional, Unrecognised Source of Tumour Neoantigens for Off-the-Shelf Therapeutic Vaccines


• RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines

• Delving into the sequence of these FS neoantigens and creation of a peptide array representing all possible neoantigen FS peptides

• How we can use this method to fast track the development of cancer vaccines

2:20 pm Key Considerations & Strategies for Technical Development of Personalised Neoantigen-based Cancer Vaccine and T-Cell Therapy

  • Narinder Singh Senior Vice President, Pharmaceutical Sciences & Manufacturing, Genocea


• Considerations for process design and specifications for a personalised neoantigen based vaccine and a personalised neoantigen based cell therapy.

• Approaches for dealing with human to human variability as well as process variability

• Key supply chain considerations for ensuring supply of personalised product to the early phase clinical trials

2:50 pm Developing Innovative Targets & Control Points for Immunotherapy Based on Neoantigens

  • Robin Fahraeus Head of Research Group, French National Institute of Health and Medical Research (INSERM)


• Exploiting the role of the mRNA translation in producing Neoantigens

• Animal models showing proof of concept

• Oncogenic virus research and work to evade the production of neoantigens

• Elucidating the biology to exploit it for new antiviral therapies

3:20 pm Afternoon Refreshments

3:50 pm Mastermind Session: Evaluating Combination Therapies


• The hasty evolvement of combination strategies

• Combinational therapies employing both neoantigen-based approaches and immune checkpoint blockade (ICB) are underway to overcome ICB-induced immune resistance and maximize antitumour immune activity

• Investigating the safety and efficacy of neoantigen vaccine therapy plus chemotherapy in adjuvant setting

• Discuss regulatory pathway and limitations to approve two new drugs

• How to identify a clear biologic effect caused by combination

• Improving clinical efficacy through Immunotherapy Combinations

• How can we block suppressive factors in the microenvironment to allow the T-cells to have a more significant impact?

4:30 pm The Use of Dermal Cancer Testis Antigen Delivery & T Cell Co-stimulation as a Neoantigen Approach in Allogenic Cell Therapy in Cancer


• The combination of an allogeneic tumour line expressing secretory gp96-Ig and OX40L-Ig is a potent stimulator of anti-tumour CD8+ T-cell immune responses

• Addition of OX40L-Ig secreting cells to gp96-Ig provides a synergistic impact on the expansion of both transferred and endogenous tumour specific T-cells

• The relationship between delivery of cancer testis antigen availability, secretory gp96 as an immune activating chaperone and local T-cell co-stimulation via OX40-Ig is being explored for success in the clinical setting

5:00 pm How Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression

  • Elisa Scarselli Chief Scientific Officer, Chief Medical Officer & Co-founder, Nouscom


Nouscom Cancer vaccines targeting neoantigens:

• Rely on effective neoantigens prediction methods

• Can encode a large number of neoantigens

• Induce a robust neoantigens’ specific CD4 and CD8 T cell immunity

• Cure large established tumours in mice when combined with checkpoint blockade

5:20 pm Chairs Closing Remarks

5:30 pm End of Day 2 & Close of Neoantigen Summit